Home

Doximity, Inc. Class A Common Stock (DOCS)

59.66
+0.69 (1.17%)

Doximity Inc is a digital platform designed specifically for medical professionals, primarily physicians, to enhance communication and collaboration within the healthcare community

The platform provides a range of tools and resources, including secure messaging, telehealth services, and access to a network of healthcare professionals, allowing doctors to connect with each other and stay updated on medical news and developments. Additionally, Doximity offers features such as electronic faxing, a comprehensive directory of healthcare providers, and opportunities for continuing medical education, all aimed at improving clinical workflows and ultimately enhancing patient care.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close58.97
Open59.05
Bid59.61
Ask59.71
Day's Range58.94 - 59.95
52 Week Range22.96 - 61.75
Volume241,097
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume1,255,433

News & Press Releases

Reasonable Growth, Debt Levels, and a High ROIC Make DOXIMITY INC-CLASS A (NYSE:DOCS) Appealing to Quality Investors.chartmill.com
Why Quality-Oriented Investors Should Consider NYSE:DOCS.
Via Chartmill · January 22, 2025
Doximity to Release Fiscal 2025 Third Quarter Results on February 6, 2025
Doximity, Inc. (NYSEDOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal third quarter ended December 31, 2024 after market close on February 6, 2025. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results.
By Doximity · Via Business Wire · January 16, 2025
Spotting Winners: Doximity (NYSE:DOCS) And Vertical Software Stocks In Q3
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at vertical software stocks, starting with Doximity (NYSEDOCS).
Via StockStory · January 14, 2025
Demystifying Doximity: Insights From 15 Analyst Reviewsbenzinga.com
Via Benzinga · January 13, 2025
Looking Into Doximity's Recent Short Interestbenzinga.com
Via Benzinga · January 8, 2025
NYSE:DOCS—Positioned as a High-Growth Stock, Ready for a Potential Breakout.chartmill.com
DOXIMITY INC-CLASS A (NYSEDOCS)—A High-Growth Stock Gearing Up for Its Next Upward Move.
Via Chartmill · January 6, 2025
Why the quality investor may take a look at DOXIMITY INC-CLASS A (NYSE:DOCS).chartmill.com
Why DOXIMITY INC-CLASS A (NYSEDOCS) qualifies as a quality stock.
Via Chartmill · December 24, 2024
Forecasting The Future: 15 Analyst Projections For Doximitybenzinga.com
Via Benzinga · December 20, 2024
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?benzinga.com
The top-performing stocks last week were TEVA, KVYO, DRI, DOCS, BIRK, JBL, NBIX, GME, RDY, and LI. Did you have any of them in your portfolio?
Via Benzinga · December 22, 2024
Kick-Save And A Beauty; Two New Swing Positionstalkmarkets.com
In this video, I review the overall market. I also provide two new swing positions, along with my exact game plan for Monday's session.
Via Talk Markets · December 21, 2024
Google Leads Five Stocks Near Buy Points, Standing Tall In Tricky Marketinvestors.com
The AI giant leads stocks near buy points as the postelection rally turns volatile.
Via Investor's Business Daily · December 21, 2024
(DOCS) - Analyzing Doximity's Short Interestbenzinga.com
Via Benzinga · December 20, 2024
DOXIMITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Doximity, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Doximity, Inc. (NYSEDOCS) on behalf of long-term stockholders following a class action complaint that was filed against Doximity on April 17, 2024 with a Class Period from February 9, 2022, to April 1, 2024. Our investigation concerns whether the board of directors of Doximity have breached their fiduciary duties to the company.
By Bragar Eagel & Squire · Via GlobeNewswire · December 19, 2024
Analyst Ratings For Doximitybenzinga.com
Via Benzinga · December 4, 2024
Veeva Systems Stock Sees IBD RS Rating Improve To 72investors.com
Veeva Systems stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 68 to 72.
Via Investor's Business Daily · December 18, 2024
Doximity Report Confirms That Telemedicine Serves Key Role in Modern Health Care
Doximity, Inc. (NYSEDOCS), the leading digital platform for U.S. medical professionals, today released its State of Telemedicine Report, showing that 83% of physician telemedicine users surveyed would like virtual care to remain a permanent part of their clinical practice. Among physicians surveyed, 84% highlighted telemedicine’s value in improving continuity of care for patients with chronic or complex conditions, and 96% emphasized its role as a complement to or, depending on the patient, a replacement for in-person care.
By Doximity · Via Business Wire · December 17, 2024
Earnings To Watch: Veeva Systems (VEEV) Reports Q3 Results Tomorrow
Healthcare software provider Veeva Systems (NASDAQVEEV) will be reporting earnings tomorrow after the bell. Here’s what investors should know.
Via StockStory · December 4, 2024
Is NYSE:DOCS suited for quality investing?chartmill.com
This article explores why quality investors may have a look at DOXIMITY INC-CLASS A (NYSEDOCS)
Via Chartmill · December 3, 2024
NYSE:DOCS: a strong growth stock preparing for the next leg up?.chartmill.com
DOXIMITY INC-CLASS A (NYSEDOCS)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
Via Chartmill · December 2, 2024
Is NYSE:DOCS a Suitable Choice for Quality Investing?chartmill.com
This article explores why quality investors may have a look at DOXIMITY INC-CLASS A (NYSEDOCS)
Via Chartmill · November 12, 2024
Two Reasons to Like DOCS and One to Stay Skeptical
Doximity has been on fire lately. In the past six months alone, the company’s stock price has rocketed 86.8%, reaching $53.60 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
Via StockStory · November 27, 2024
3 Chart Patterns That Cut Through The Market’s Chaostalkmarkets.com
There are endless ways of analyzing price data. But the truth is, I don’t use 90% of it. What I find most useful when analyzing stock charts is pattern recognition. Today, I’ll review three of the patterns that I use regularly in my trading research.
Via Talk Markets · November 16, 2024
This Campbell Soup Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursdaybenzinga.com
Via Benzinga · November 14, 2024
This Caterpillar Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesdaybenzinga.com
Via Benzinga · November 13, 2024
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · November 12, 2024